Sarepta Therapeutics Inc (SRPT): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Sarepta Therapeutics ( SRPT) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day down 0.3%. By the end of trading, Sarepta Therapeutics fell $1.04 (-3.2%) to $31.54 on heavy volume. Throughout the day, 2,516,025 shares of Sarepta Therapeutics exchanged hands as compared to its average daily volume of 1,591,700 shares. The stock ranged in price between $31.25-$32.96 after having opened the day at $32.90 as compared to the previous trading day's close of $32.58. Other companies within the Health Care sector that declined today were: Pingtan Marine Enterprise ( PME), down 82.9%, Aastrom Biosciences ( ASTM), down 43.4%, Alimera ( ALIM), down 20.7% and Savient Pharmaceuticals ( SVNT), down 14.5%.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Sarepta Therapeutics has a market cap of $1.2 billion and is part of the drugs industry. Shares are up 35.4% year to date as of the close of trading on Monday. Currently there are 8 analysts that rate Sarepta Therapeutics a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Sarepta Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share.

On the positive front, Osiris Therapeutics ( OSIR), up 138.7%, IsoRay ( ISR), up 18.2%, GW Pharmaceuticals PLC ADR ( GWPH), up 16.4% and Prana Biotechnology ( PRAN), up 10.3% , were all gainers within the health care sector with GlaxoSmithKline ( GSK) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.